| Tekturna (aliskiren) / PDL |
| Completed | 2 | 445 | Japan | Aliskiren | Novartis | Hypertension | 03/05 | 03/05 | | |
NCT00097955: Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria |
|
|
| Completed | 2 | 496 | US, Canada, Europe, RoW | aliskiren | Novartis Pharmaceuticals | Diabetic Nephropathy | 04/07 | 04/07 | | |
| Completed | 2 | 68 | Europe, RoW | Aliskiren, Valsartan, Placebo to aliskiren, Placebo to valsartan | Novartis | Hypertension | 10/09 | 10/09 | | |
NCT00939588: Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients |
|
|
| Completed | 2 | 88 | RoW | Aliskiren/ Valsartan, Telmisartan/ Ramipril | Novartis Pharmaceuticals | Hypertension | 12/09 | | | |
NCT00417170: Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome |
|
|
| Completed | 2 | 48 | US | Aliskiren, Amlodipine, Placebo Aliskiren, Placebo Amlodipine | Novartis Pharmaceuticals | High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction | 07/10 | 07/10 | | |
| Terminated | 2 | 31 | Europe | Aliskiren/amlodipine, SPA100, Amlodipine, Placebo to Aliskiren/amlodipine, Placebo to Amlodipine | Novartis Pharmaceuticals | Hypertension, Ankle Edema | 11/10 | 11/10 | | |
NCT00498433 / 2005-004566-16: Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension |
|
|
| Terminated | 2 | 46 | Europe | Aliskiren, SPP100, Amlodipine, Placebo of Aliskiren, Placebo of amlodipine | Novartis | Hypertension, Abdominal Obesity | 03/12 | 03/12 | | |
NCT01480791: Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries |
|
|
| Withdrawn | 2 | 0 | Canada | Aliskiren vs. hydrochlorothiazide, Aliskiren is Tekturna or Rasilez, Hydrochlorothiazide, Hydrochlorothiazide is a generic drug. | Sir Mortimer B. Davis - Jewish General Hospital, Novartis Pharmaceuticals | Hypertension, Diabetes | 12/13 | 12/13 | | |
2004-000895-16: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of aliskiren on proteinuria when added to standardized losartan therapy and optimal antihypertensive therapy in patients with hypertension and Type 2 diabetes mellitus |
|
|
| | 2 | 50 | Europe | Aliskiren, SPP100, Cozaar 50 mg; Cozaar 100 mg, Cozaar 50 mg; Cozaar 100 mg | Novartis Ireland Ltd, Novartis Pharma Services AG, Novartis Farmacéutica, S.A., Novartis Pharmaceuticals UK Ltd, NOVARTIS FARMA | patients with hypertension, Type 2 DM and proteinuria | | 04/07 | | |
2005-001252-21: An open-label, multiple-dose study to evaluate the pharmacokinetics, safety and tolerability of SPP100 (Aliskiren) and Atenolol (Tenormin®) administered alone and in combination in healthy subjects |
|
|
| Completed | 2 | 22 | Europe | Aliskiren, Tenormin, SPP100, | Novartis Pharma Services AG | Hypertension | | | | |
2005-001176-12: A randomized, double-blind, double-dummy, parallel-group study to compare the effects of multiple dose administration of aliskiren and irbesartan on biomarkers of inflammation and cardiovascular risk in patients with hypertension and metabolic syndrome |
|
|
| Completed | 2 | 120 | Europe | Aliskiren, Irbesartan, SPP100, | Novartis Pharma Services AG | Hypertension | | 05/07 | | |
2009-016902-17: Direct renin inhibitor (aliskiren)and carotid plaques instability markers in hypertensive patients requiring carotid endoarterectomy |
|
|
| | 2 | 90 | Europe | Coated tablet | AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI | Essential hypertension. | | | | |
NCT00834041 / 2008-005802-37: A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age |
|
|
| Completed | 1/2 | 39 | US, Europe, RoW | Aliskiren 3.125 mini-tablets | Novartis | Hypertension | 01/10 | 01/10 | | |
